Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

Abeona Therapeutics IncTrade
GraniteShares 2x Long NVDA Daily ETFTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while GraniteShares 2x Long NVDA Daily ETF trades at $36.41. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.

ABEONVDL
Market Cap
$421.19M
Sector
HealthLeveraged / Inverse
52-Week High
$7.45$43.02
52-Week Low
$4.17$21.76
Enterprise Value
$276.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.

Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.

GraniteShares 2x Long NVDA Daily ETF

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.32, up 5.7% in 24 hours, reflecting strong bullish momentum from its underlying asset NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward movement, though the RSI suggests mild overbought conditions. Recent news highlights NVDL's leveraged exposure to NVIDIA's AI-driven growth, with the ETF capturing amplified returns from NVDA's performance, including a 12.66% year-to-date gain as of June 8, 2026, per 24/7 Wall Street.

The outlook for NVDL is tied to NVIDIA's continued dominance in AI chips, with potential for significant gains during bullish phases but high volatility risks due to daily reset leverage. Key risks include compounded losses during NVDA downturns, as seen in a 12% single-day drop on June 5, 2026. Investors should weigh the ETF's amplified returns against its inherent decay in volatile markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

Read more on NVDL